Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Robustness of Tiotropium Zephir Inhaler in COPD
NCT06254664Phase 1Completed
- Sponsor
- Xiromed
- Start
- Oct 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of tiotropium in chronic obstructive pulmonary disease (COPD), sponsored by Xiromed. Primary endpoint: In vitro Measurement of Emitted Dose at 3 weeks. Started Oct 2022; status: completed.
02
Drugs
tiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06254664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254664.